AlloVir
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1100 Winter St, Waltham, Massachusetts, ...Phone Number
(617) 433-2605Website
www.allovir.comRevenue
<$5 MillionStock Symbol
ALVRIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About AlloVir
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.Explore more
AlloVir Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AlloVir your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if AlloVir had a recent Job posting/layoffs
Funding: Get notified immidiatlly once AlloVir has new funding data
Congratulate Masked Content for being promoted to Masked Content at AlloVir
Earning: See what the market has to say on AlloVir recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if AlloVir has recently received funding, and reach out quickly before it becomes old news!
AlloVir, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when AlloVir launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if AlloVir is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined AlloVir as Masked Content
Find 2 more new buyers
Compare Similar Companies to AlloVir
Compare insights from companies similar to AlloVir, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
AlloVir is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
AlloVir is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about AlloVir.
AlloVir financials insights
Gather financial insights about AlloVir, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$30M
2020
Series B
$120M
Stock Offering
$276M
AlloVir Tech Stack
A closer look at the technologies used by AlloVir
See more technologies
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Earnings
Marketing Relationships
Earnings
Operations
Earnings
AlloVir News & Media
Kalaris and AlloVir Inc. complete merger - Ophthalmology Times
The combined companies will operate under the name Kalaris Therapeutics, Inc. and expects to report initial data from part 1 of its ongoing phase 1 clinical trial of TH103 in treatment-naïve nAMD patients in the second half of 2025.Kalaris and AlloVir Announce Stockholder Approval of Merger
Combined company expected to trade on Nasdaq under “KLRS” after closing Combined company expected to trade on Nasdaq under “KLRS” after closingAllovir's general counsel Edward Miller sells $180 in stock - Investing.com
Allovir's general counsel Edward Miller sells $180 in stockAllovir's chief accounting officer sells $146 in common stock - Investing.com
Allovir's chief accounting officer sells $146 in common stock
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AlloVir
Sign Up For FreeTo access detailed company insights
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ade... Read More
